ML230 is a selective ATP-binding cassette (ABC) transporter ABCG2 inhibitor. It 36-fold selective for ABCG2 over ABCB1 (EC50s: 0.13 μM and 4.65 μM, respectively).
D-4418 is a PDE4 inhibitor. It has been in development as a novel anti-inflammatory therapy with asthma and chronic obstructive pulmonary disease being primary indications.